ZA200107371B - Method for selecting improved vectors. - Google Patents
Method for selecting improved vectors. Download PDFInfo
- Publication number
- ZA200107371B ZA200107371B ZA200107371A ZA200107371A ZA200107371B ZA 200107371 B ZA200107371 B ZA 200107371B ZA 200107371 A ZA200107371 A ZA 200107371A ZA 200107371 A ZA200107371 A ZA 200107371A ZA 200107371 B ZA200107371 B ZA 200107371B
- Authority
- ZA
- South Africa
- Prior art keywords
- retroviral
- genome
- nucleotide sequence
- packaging
- vector
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims description 84
- 238000000034 method Methods 0.000 title claims description 43
- 230000001177 retroviral effect Effects 0.000 claims description 141
- 210000004027 cell Anatomy 0.000 claims description 98
- 238000004806 packaging method and process Methods 0.000 claims description 90
- 230000003612 virological effect Effects 0.000 claims description 39
- 239000002245 particle Substances 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 37
- 125000003729 nucleotide group Chemical group 0.000 claims description 37
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 230000002458 infectious effect Effects 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 15
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 231100000219 mutagenic Toxicity 0.000 claims description 7
- 230000003505 mutagenic effect Effects 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 24
- 241000700605 Viruses Species 0.000 description 20
- 241001430294 unidentified retrovirus Species 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 9
- 210000000605 viral structure Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000003146 transient transfection Methods 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 229960004927 neomycin Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 4
- 102100034353 Integrase Human genes 0.000 description 4
- 241000714177 Murine leukemia virus Species 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 108010078428 env Gene Products Proteins 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 108700004026 gag Genes Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 241000714175 Abelson murine leukemia virus Species 0.000 description 2
- 241000713840 Avian erythroblastosis virus Species 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714475 Fujinami sarcoma virus Species 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000002976 reverse transcriptase assay Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000713834 Avian myelocytomatosis virus 29 Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000713859 FBR murine osteosarcoma virus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 101150047047 gag-pol gene Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
ol . 4°
METHOD FOR SELECTING IMPROVED VECTORS
The present invention relates to a method for improving the packaging efficiency of retroviral vectors.
Retroviral vectors are now widely used as vehicles to deliver genes into cells. Their popularity stems from the fact that they are safe. easy to produce and mediate stable integration of the gene that they carry into the genome of the target cell. This enables long-term expression of the delivered gene (Miller, 1997).
The production of retroviruses is far from efficient. Typically, less than ten percent of viral particles in a retroviral stock is infectious because the rest of the particles do not carry a viral genome. In the wild type virus, the gag/gag-pol gene products are translated from , the full-length RNA transcript, which is also packaged. One hypothesis for the poor packaging efficiency lies in the competition between the processes of packaging and the translation (Sonstegard and Hackett 1996). This is due to the signal for packaging being located very close to the ribosomal binding site. Binding of the gag protein to the packaging signal obstructs the binding of ribosomes and thus inhibits its own translation.
During the course of evolution, a stronger packaging signal was not selected because it will bind more strongly to the gag protein and limit its production. 23
In the production of retroviral vectors, however, the gag/gag-pol and genome components have been separated into different expression cassettes (Soneoka et al., 1995). The processes of packaging and translation have therefore been uncoupled. Hence, it is theoretically possible that a viral genome could be developed with high packaging 50 efficiency without compromising the production of gag/gag-pol.
Previous attempts in obtaining improved novel retroviral sequences have either been through serial passage of the replication competent virus (Taplitz and Coffin, 1997) or by : SUBSTITUTE SHEET (RULE 26)
© W'O 00771693 PCT/GB00/01964 ) = in vitro selection procedures (Allen er al.. 1996; Berglund et al., 1997). Serial passage Ot the virus takes a long time. As for in vitro selection, there are many parameters that need to be optimised. These include the conditions required to perform mutagenesis and selection. Furthermore. it often relies on the size of library of random mutations. which in turn depends on the successful cloning of the mutagenised DNA.
Furthermore. none of these previous attempts to produce novel retroviral sequences have focussed on trying to improve retroviral packaging beyond its natural efficiency.
We have found, while investigating effects of the stoichiometry of viral components on retroviral production using a transient transfection system, that it is possible to produce a viral stock in which substantially all the particles are infectious by ensuring that they are all filled with genomic RNA. Our results show that this may be achieved by using a lower i proportion of gag/gag-pol construct compared with env and genome. -
Accordingly, the present invention provides a method for enhancing the efficiency of retroviral packaging which method comprises expressing in a producer cell at least a first nucleotide sequence encoding a retroviral gag-pol polypeptide, a second nucleotide sequence encoding a retroviral envelope polypeptide and a third nucleotide sequence encoding a retroviral genome wherein the ratio of the first nucleotide sequence to the second and third nucleotide sequence is x:y:z wherein x is less than 1 and y and z are 1. In other words, the ratio of the first nucleotide sequence to the second and third nucléotide sequence is less than 1:1:1.
Preferably, the ratio of the first nucleotide sequence encoding a retroviral gag-pol polypeptide to the second and third nucleotide is less than 0.8:1:1 or 0.5:1:1, more preferably less than 0.2:1:1.
Preferably the proportion of the number of infectious retroviral particles to the total number of retroviral particles produced is greater than 15%, more preferably greater than 25% or 50%.
SUBSTITUTE SHEET (RULE 26)
-3- . 4
The present invention also provides a composition comprising retroviral particles produced according to the method of the invention described above, and a producer cell which has enhanced retroviral packaging efficiency due to the fact it expresses a lower proportion of gag/gag-pol construct compared with env and genome.
Another way to increase the proportion of infectious particles would be to improve the packaging efficiency of the genome by modifying the packaging signal. However, to date, there have only been attempts to identify naturally occurring viral packaging signals and incorporate these into retroviral vectors (Adam and Miller, 1988). Such vectors will. at best, only be packaged with wild type efficiencies.
We have therefore developed an in vivo strategy to select a vector genome with improved packaging efficiency which involves shuttling a retroviral vector between a mutagenic strain of Epicurian coli, where random mutations are introduced in its sequence, and mammalian cells, where selection is made for better packaging efficiency (Figure 2).
Increasing the packaging efficiency results in viral stocks that contain more infectious particles. This leads to higher end-point titres. Furthermore, transduction efficiencies are also improved because there are fewer defective particles that will otherwise obstruct the binding of infectious particles to the target cell receptors.
The in vivo method of selection that we describe is rapid and easy to perform. It only involves extracting and introducing DNA from mammalian and bacteria cells. These are extremely well characterised and optimised processes. 23
Accordingly the present invention also provides a method for selecting an improved retroviral genome having an improved packaging efficiency which method comprises: (a) introducing one or more random mutations into a retroviral genome comprising a packaging signal; (b) introducing the mutagenised retroviral genome into a host cell expressing viral polypeptides required for packaging the retroviral genome; (c) determining whether retroviral packaging efficiency in the cell is improved as compared with a retroviral genome comprising a non-mutated packaging signal; (d) selecting a viral genome which has improved packaging efficiency.
SUBSTITUTE SHEET (RULE 26)
° WO 00/71693 PCT/GB00/01964 ¥ ty
Preferably the method comprises an additional step (e) of determining the sequence of all or part of the viral genome to identify the sequence of the packaging signal.
Preferably step (a) is carried out in a bacterial strain which introduces random mutations into the retroviral genome. A particularly preferred bacterial strain is a mutagenic strain of
Epicurian coli.
Preferably the host cell of steps (b) and (c) is a mammalian cell. In a particularly preferred embodiment. the host cell comprises at least: (1) a first nucleotide sequence encoding a retroviral gag-pol polypeptide; (i1) a second nucleotide sequence encoding a retroviral envelope polypeptide; and (iii) a third nucleotide encoding a retroviral genome comprising a non-mutated packaging signal, wherein the third nucleotide is present as part of a nucleic acid vector which lacks a . selectable marker; the mutagenised retroviral genome is present as part of a nucleic acid vector which contains the selectable marker; and the ratio of the vector comprising the } third nucleotide to the vector comprising the mutagenised retroviral genome is greater than 2:1, preferably greater than 5:1.
It is preferred that the packaging efficiency, measured as the proportion of the number of infectious retroviral particles to the total number of retroviral particles produced is greater than 25%, more preferably greater than 50%. The number of infectious retroviral particles in a viral stock (i.e. the titre) may be determined by techniques known in the art, for example by transducing mammalian cells. The total number of retroviral particles may be measured by, for example, reverse transcription assays.
The present invention also provides a retroviral genome obtained by the selection method of the invention. Preferably the retroviral genome has a packaging efficiency, measured as the proportion of the number of infectious retroviral particles to the total number of retroviral particles produced of greater than 25%, more preferably greater than 50%.
SUBSTITUTE SHEET (RULE 26)
Ld 4
The retroviral genome's packaging signal may be cloned from the improved retroviral genome, or its sequence determined and used to synthesis a packaging signal for use in producing an improved retroviral genome. Thus the invention also provides a retroviral packaging signal obtainable from a retroviral genome selected by the method of the invention.
The present invention further provides a non-naturally occurring retroviral packaging signal, which as measured when part of a retroviral genome, has a packaging efficiency of at least 15%, preferably at least 20, 25. 35 or 50%.
In a further aspect the present invention provides a nucleic acid comprising a retroviral packing signal of the invention and a retroviral vector comprising a retroviral packing signal of the invention. The retroviral vector may be a lentiviral vector.
The present invention also provides a producer cell which comprises a retroviral genome, retroviral packaging signal or retroviral vector according to the invention. }
The present invention also provides a composition comprising infectious retroviral particles produced according to the methods of the invention and/or using improved " retroviral genomes obtained by the methods of the invention. Such compositions may, for example, be used in therapy.
Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook er al., Molecular Cloning, A Laboratory Manual (1989) and Ausubel er al., Current Protocols in Molecular Biology (1995), John Wiley & Sons,
Inc.
Retroviruses
The retroviral vectors used in the production of mutagenised retroviral genomes and infectious retroviruses according to the methods of the present invention may be derived
SUBSTITUTE SHEET (RULE 26)
from or may be derivable from any suitable retrovirus. A large number of different retroviruses have been identified. Examples include: murine leukemia virus (MLV), g human immunodeficiency virus (HIV), simian immunodeficiency virus, human T-cell leukemia virus (HTLV). equine infectious anaemia virus (EIAV), mouse mammary 3 tumour virus (MMTV). Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV),
Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV),
Moloney murine sarcoma virus (Mo-MSV), Abelson murine leukemia virus (A-MLV),
Avian myelocytomatosis virus-29 (MC29), and Avian erythroblastosis virus (AEV). A detailed list of retroviruses may be found in Coffin er al, 1997, “Retroviruses”, Cold
Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 758-763.
Details on the genomic structure of some retroviruses may be found in the art. By way of example, details on HIV and Mo-MLV may be found from the NCBI Genbank (Genome
Accession Nos. AF033819 and AF033811, respectively). } The lentivirus group can be split even further into “primate” and “non-primate”, Examples of primate lentiviruses include human immunodeficiency virus (HIV), the causative agent of human auto-immunodeficiency syndrome (AIDS), and simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype “slow virus” visna/maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).
A distinction between the lentivirus family and other types of retroviruses is that lentiviruses have the capability to infect both dividing and non-dividing cells (Lewis er al1992 EMBO. J 11: 3053-3058; Lewis and Emerman 1994 J. Virol. 68: 510-516). In contrast, other retroviruses - such as MLV - are unable to infect non-dividing cells such as those that make up, for example, muscle, brain, lung and liver tissue.
Preferred vectors optimisable by the method of the present invention are recombinant retroviral vectors, in particular recombinant lentiviral vectors, in particular minimal lentiviral vectors, teachings relating to which are disclosed in WO 99/32646 and in
W098/17815.
SUBSTITUTE SHEET (RULE 26)
The basic structure of a retrovirus genome is a 5° LTR and a 3° LTR, between or within which are located a packaging signal to enable the genome to be packaged. a primer binding site, integration sites to enable integration into a host cell genome and gag, pol and env genes encoding the packaging components - these are polypeptides required for the assembly of viral particles. More complex retroviruses have additional features. such as rev and RRE sequences in HIV. which enable the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell.
Inthe provirus, these genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration, and transcription. LTRs also serve as enhancer-promoter sequences and can control the expression of the viral genes.
Encapsidation of the retroviral RNAs occurs by virtue of a psi sequence located at the 5° end of the viral genome. : 15 : The LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3’ end of the RNA. Ris derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5° end of the RNA. The sizes of the three elements can vary considerably among different retroviruses.
In a defective retroviral vector genome gag, pol and env may be absent or not functional.
The R regions at both ends of the RNA are repeated sequences. US and U3 represent unique sequences at the 5’ and 3’ ends of the RNA genome respectively.
In a typical retroviral vector for use in gene therapy, at least part of one or more of the gug, pol and env protein coding regions essential for replication may be removed from the virus.
This makes the retroviral vector replication-defective. The removed portions may even be replaced by a nucleotide sequence of interest (NOI), such as a nucleotide sequence encoding a therapeutic product, to generate a virus capable of integrating its genome into a host genome but wherein the modified viral genome is unable to propagate itself due to a lack of structural proteins. When integrated in the host genome, expression of the NOI occurs - resulting in, for example, a therapeutic and/or a diagnostic effect. Thus. the
SUBSTITUTE SHEET (RULE 26)
© WO 00/71693 PCT/GB00/01964 rs - -8- transfer of an NOI into a site of interest is typically achieved by: integrating the NOI into the recombinant viral vector; packaging the modified viral vector into a virion coat; and allowing transduction of a site of interest - such as a targeted cell or a targeted cell population.
A minimal retroviral genome for use in the present invention will therefore comprise (57) R - U5 - one or more first nucleotide sequences - U3-R (3°). However, the plasmid vector used to produce the retroviral genome within a host cell/packaging cell will also include transcriptional regulatory control sequences operably linked to the retroviral genome to lo direct transcription of the genome in a host cell/packaging cell. These regulatory sequences may be the natural sequences associated with the transcribed retroviral sequence, i.e. the 5° U3 region. or they may be a heterologous promoter such as another viral promoter, for example the CMV promoter.
Some retroviral genomes require additional sequences for efficient virus production. For ] example, in the case of HIV, rev and RRE sequence are preferably included. However the requirement for rev and RRE can be reduced or eliminated by codon optimisation.
Codon optimisation causes to an improvement in codon usage. By way of example, alterations to the coding sequences for viral components may improve the sequences for codon usage in the mammalian cells or other cells which are to act as the producer cells for retroviral vector particle production. Many viruses, including HIV and other lentiviruses. use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved. Codon usage tables are known in the art for mammalian cells, as well as for a variety of other organisms.
The rerroviral vector may be produced using a codon optimised gag and a codon optimised pol or a codon optimised env.
Accessory genes encode variety of accessory proteins capable of modulating various aspects of retroviral replication and infectivity. These proteins are discussed in Coffin et al. Chapters 6 and 7. Examples of accessory proteins in lentiviral vectors include but are
SUBSTITUTE SHEET (RULE 26)
-9. - nN not limited to tat, rev. nef, vpr, vpu. vif, vpx. An example of a lentiviral vector useful in the present invention is one which has all of the accessory genes removed except rev.
Le Once the retroviral vector genome is integrated into the genome of its target cell as proviral = 5s DNA. the nucleotide sequences of interest need to be expressed. In a retrovirus, the - promoter is located in the 3° LTR U3 region of the provirus. In retroviral vectors, the - promoter driving expression of a therapeutic gene may be the native retroviral promoter in - the 5° U3 region, or an alternative promoter engineered into the vector. The alternative - promoter may physically replace the 5’ U3 promoter native to the retrovirus, or it may be incorporated at a different place within the vector genome such as between the LTRs. : Thus, an NOI will also be operably linked to a transcriptional regulatory control sequence to allow transcription of the NOI to occur in the target cell. The control sequence will : typically be active in mammalian cells. The control sequence may, for example. be a viral promoter such as the natural viral promoter or a CMV promoter or it may be a mammalian promoter. It is particularly preferred to use a promoter that is preferentially active in a . : particular cell type or tissue type in which the virus to be treated primarily infects. Thus, in one embodiment. a tissue-specific regulatory sequences may be used. The regulatory control sequences driving expression of the one or more first nucleotide sequences may be constitutive or regulated promoters. Another particularly preferred regulatory construct comprises an hypoxia responsive element, such as is described in W099/15684, the contents of which are incorporated herein by reference.
Replication-defective retroviral vectors are typically propagated, for example to prepare suitable titres of the retroviral vector for subsequent transduction, by using a combination of a packaging or helper cell line and the recombinant vector. That is to say, that the three packaging proteins can be provided in trans (see below).
Producer cells 50
Retroviral producer cells are cells that contain all the elements necessary for the production of infectious recombinant retroviruses. These elements may be permanently present stably
SUBSTITUTE SHEET (RULE 26)
within the cell (for example integrated in the cell genome or in episomal form) and/or transiently provided, for example by transfection.
A packaging cell, by contrast, expresses one or more viral components required for packaging retroviral DNA but lacks a psi region. Packaging cell lines typically comprise one or more of the retroviral gag, pol and env genes. Thus, the packaging cell line produces the structural proteins required for packaging retroviral DNA but it cannot bring about encapsidation due to the lack of a psi region. However, when a recombinant vector carrving a defective viral genome comprising a psi region and typically a nucleotide sequence of interest (NOI) is introduced into the packaging cell line, the helper proteins can package the psi-positive recombinant vector to produce the recombinant virus stock.
This virus stock can be used to transduce cells to introduce the NOI into the genome of the target cells. It is preferred to use a psi packaging signal, called psi plus, that contains additional sequences spanning from upstream of the splice donor to downstream of the gag start codon since this has been shown to increase viral titres.
The recombinant virus whose genome lacks all genes required to make viral proteins can } tranduce only once and cannot propagate. These viral vectors which are only capable of a single round of transduction of target cells are known as replication defective vectors.
Hence. the NOI is introduced into the host/target cell genome without the generation of potentially harmful retrovirus. A summary of the available packaging lines is presented in
Coffin er al.. 1997.
Packaging cell lines in which the gag, pol and env viral coding regions are carried on separate expression plasmids that are independently transfected into a packaging cell line are preferably used. This strategy, sometimes referred to as the three plasmid transfection method (Soneoka er al, 1995) reduces the potential for production of a replication- competent virus since three recombinant events are required for wild type viral production.
As recombination is greatly facilitated by homology, reducing or eliminating homology between the genomes of the vector and the helper can also be used to reduce the problem of replication-competent helper virus production.
SUBSTITUTE SHEET (RULE 26)
11- i -
An alternative to stably transfected packaging cell lines 1s to use transiently transfected cell lines. Transient transfections may advantageously be used to measure levels of vector production when vectors are being developed. In this regard, transient transfection avoids } the longer time required to generate stable vector-producing cell lines and may also be used if the vector or retroviral packaging components are toxic to cells. Components . typically used to generate retroviral vectors include a plasmid encoding the gag/pol ) proteins. a plasmid encoding the env protein and a plasmid containing an NOI. Vector production involves transient transfection of one or more of these components into cells containing the other required components. If the vector encodes toxic genes or genes that interfere with the replication of the host cell, such as inhibitors of the cell cycle or genes that induce apotosis, it may be difficult to generate stable vector-producing cell lines, but transient transfection can be used to produce the vector before the cells die. Also. cell lines have been developed using transient transfection that produce vector titre levels that are comparable to the levels obtained from stable vector-producing cell lines.
Producer cells can be produced either from packaging cells by introducing into the packaging cell any remaining viral components required for infectious retrovirus production or they can be produced by introduction into a non-packaging cell, such as a 293T cell, of all the components required for infectious retrovirus production.
Producer cells/packaging cells can be of any suitable cell type. Most commonly, mammalian producer cells are used but other cells. such as insect cells are not excluded.
Clearly, the producer cells will need to be capable of efficiently translating the env and gag, pol mRNA. Many suitable producer/packaging cell lines are known in the art. The skilled person is also capable of making suitable packaging cell lines by, for example stably introducing a nucleotide construct encoding a packaging component into a cell line.
It is highly desirable to use high-titre virus preparations in both experimental and practical applications. Techniques for increasing viral titre include using a psi plus packaging signal as discussed above and concentration of viral stocks. In addition, the use of different envelope proteins, such as the G protein from vesicular-stomatitis virus has improved titres following concentration to 10° per ml. However, typically the envelope protein will be chosen such that the viral particle will preferentially infect cells that are infected with the
SUBSTITUTE SHEET (RULE 26)
N , -12- virus which it desired to treat. For example where an HIV vector is being used to treat
HIV infection, the env protein used will be the HIV env protein.
Mutagenesis of retroviral genomes
In vitro evolution has gained much attention in recent times. It involves introducing random mutations in a DNA sequence followed by a selection procedure, thereby producing a gene with an improved or novel function (Joyce, 1992). The strength of the technology lies in the fact that there is no requirement to understand how a gene functions in order to change or improve it. All that is necessary is the generation of random mutations in the DNA sequence at a high frequency and a procedure to select the desired changes. There are several methods of generating random mutations. These include error- prone PCR (Beaudry and Joyce. 1992), DNA shuffling (Stemmer, 1994) and. more recently, transformation of a mutagenic strain of Epicurian coli (Bomscheuer et al., 1998).
Other techniques are also known in the art for producing mutations (such as the use of } ionising radiation or chemical mutagens). It is preferred in the context of the present invention to use a mutagenic bacterial strain such a mutagenic strain of Epicurian coli introduce mutations in a retroviral genome.
Generally, the retroviral genome will be present as part of a nucleic acid vector. Where mutagenesis is to take place in a host cell, in vivo, the nucleic acid vector will be chosen to be compatible with the host cell. It is particularly preferred to use a shuttle vector, i.e. a vector which can be propagated in more than one type of host (such as bacteria and mammalian cells). This enables mutagenesis to take place in, for example, a bacterial ~5 strain and then the mutagenised vector extracted and purified using standard techniques before introduction into the mammalian cell without the need for any cloning.
Thus the first stage is to subject the retroviral genome to mutagenesis. In a preferred embodiment this is achieved by transforming the retroviral genome into Epicurian coli cells such as XL1-Red cells (Stratagene). The pool of resulting mutants is then extracted using standard techniques such as large-scale plasmid isolation protocols.
SUBSTITUTE SHEET (RULE 26)
-13- N »
Selection
Typically, a pool of mutagenised retroviral genomes are then introduced into host cells that = are capable of packaging the genome (see above for details of packaging cells and = : producer cells). Competition for packaging is set up by co-transfecting the host cells with 7 a non-mutagenised retroviral genome present as part of a vector which lacks a selectable marker suitable for use in the host cell. By contrast, the mutagenised retroviral genome is present as part of a vector which contains the selectable marker. Preferably, the amount of = non-mutagenised genome is at least double, more preferably at least five times the amount of mutagenised genome. - Retroviral particles produced by the host cells are then used to transduce further cells. such - as COS cells. Any resulting neomycin-resistant cells contain mutagenised retroviral genomes which are packaged more efficiently than the wild type retroviral genome. The retroviral particles produced by these cells can be tested to determined their packing : efficiency as described above. }
Selected retroviral clones may be isolated and optionally subjected to additional mutagenesis/selection steps. Selected retroviral clones may also be isolated and their nucleotide sequence determined to establish the particular mutation or mutations which result in improved packaging efficiency. Typically these will be within the packing signal sequence.
The improved retroviral genomes may be used as the basis of constructing improved 2s retroviral vectors, for example for use in delivering a therapeutic gene to a patient. In particular, the modified sequences may be cloned into existing retroviral vectors.
Uses
The application of the methods of the invention will enable the production of compositions comprising retroviral particles wherein a greater proportion are infectious than has been possible previously.
SUBSTITUTE SHEET (RULE 26)
x . -14-
The infectious retroviral particles may comprise one or more coding sequences encoding therapeutic products. Therapeutic products include. but are not limited to. cytokines. hormones. antibodies, immunoglobulin fusion proteins, enzymes, immune co-stimulatory molecules. anti-sense RNA. a transdominant negative mutant of a target protein, a toxin, a 5s conditional toxin. an antigen, a single chain antibody, tumour suppresser protein and crowth factors. When included, such coding sequences are operatively linked to 2 suitable promoter.
Preferably the viral particles are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Thus. the present invention also provides a pharmaceutical composition for treating an individual, wherein the composition comprises a therapeutically effective amount of the viral particle of the present invention. together with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The pharmaceutical composition may be for human or animal usage. } The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase the viral entry into the target site (such as for example a lipid delivery system).
The pharmaceutical composition may be formulated for parenteral, intramuscular, 75 intravenous, intracranial, subcutaneous, intraocular or transdermal administration.
Where appropriate, the pharmaceutical compositions can be administered by any one or more of: inhalation. in the form of a suppository or pessary. topically in the form of a lotion. solution, cream, ointment or dusting powder, by use of a skin patch. orally in the 50 form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously. intramuscularly or subcutaneously. For
SUBSTITUTE SHEET (RULE 26)
-15- R A parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
The amount of virus administered is typically in the range of from 10° to 10" pfu, preferably from 10° to 10° pfu, more preferably from 10° to 10” pfu. When injected. typically 1-10 pl of virus in a pharmaceutically acceptable suitable carrier or diluent is administered.
Where the therapeutic sequence is under the control of an inducible regulatory sequence, it may only be necessary to induce gene expression for the duration of the treatment. Once the condition has been treated, the inducer is removed and expression of the NOI is stopped. This will clearly have clinical advantages. Such a system may, for example, involve administering the antibiotic tetracycline, to activate gene expression via its effect on the tet repressor/VP16 fusion protein.
The invention will now be further described in the Examples which follow. which are intended as an illustration only and do not limit the scope of the invention. The Examples refer to the Figures.
Figure | — Graph of viral titres vs amount of DNA encoding viral components
Figure 2 - Reverse transcriptase assays of viral stocks prepared from different amounts of the three components.
Spots: 1, 0.1 ug of all three plasmids; 2. 1 pg of pHIT60, 0.1 pg of pHIT111 and pHIT456; 3, 1 ug of pHIT111, 0.1 pg of pHIT60 and pHIT456; 4.1 pg of pHIT456, 0.1 png of pHIT60 and pHIT111; 3, 1 pg of all three plasmids; 6, 0.1 pg of pHIT60. 1 pug of pHIT111 and pHIT456. Sample 6 has similar titres to sample 3 although its reverse transcriptase activity is lower.
Figure 3 — In vivo selection of a vector with higher packaging efficiency.
SUBSTITUTE SHEET (RULE 26)
© WO 00/71693 PCT/GB00/01964
Figure 4 — Map of shuttle vector pMEL.
Figure 5 — Diagrammatic representation of scheme for testing shuttle vector 3
Example 1 — Effect of each viral component on viral titres
We have investigated effects of the stoichiometry of viral components on retroviral production using a transient transfection system. The murine leukaemia virus (MLV) genome was segregated into three different plasmids: one containing the gag/gag-pol, one containing the env and another containing the long terminal repeats, packaging signal and the lacZ marker (genome construct).
Firstly, we determined the conditions under which none of the three viral components are saturating. The results shown in Figure 1 indicate that since none of the viral components are saturating at 0.1 pg of each plasmid, then 0.1 pug would be a suitable starting point from which the amount of each component could then be raised.
Raising the amount of one plasmid with respect to the other two, we then measured the viral titres and compared them to the titres produced when equal amounts of all three plasmids were used.
The number of infectious particles was determined by X-gal staining of transduced
NIH3T3 cells, while the total number of viral particles was measured by reverse transcriptase assay.
The results shown in Table 1 indicate that genome is limiting and that 10-fold more genome increased titres. It was also found that similar titres could be achieved using 10 times less of the gag/gag-pol component compared to using equal amounts of all three components (Table 1). However, the former viral stock had a lower reverse transcriptase activity compared to the latter (Figure 2 — lanes 5 and 6), suggesting that the viral stock
SUBSTITUTE SHEET (RULE 26)
» . a produced using less gag/gag-pol contained a larger infectious-particles-to-total-particles ratio. These results showed that it is possible to produce a viral stock in which all the particles are infectious by ensuring that they are all filled with genomic RNA.
Table 1. Effect of each component on viral titres.
Amounts of plasmids used in transfection (ug)* Titres (L.f.u./m})° pHIT60 pHIT111 pHIT456 (env) (gag/eag-pol (genome) “Different amounts of plasmids were used to transfect 293T cells in 6 cm dishes using
FuGene6 transfection reagent (Boehringer Mannheim). “Viral titres were measured as the number of lacZ forming units (1.f.u.) per ml as observed by X-gal staining.
Example 2 - in vivo strategy to select a vector genome with improved packaging efficiency.
We have also developed an in vivo strategy to select a vector genome with improved packaging efficiency which involves shuttling a retroviral vector between a mutagenic strain of Epicurian coli, where random mutations are introduced in its sequence, and mammalian cells, where selection is made for better packaging efficiency (Figure 3).
Selection is effected by competition for packaging by vectors containing the existing packaging signal.
SUBSTITUTE SHEET (RULE 26)
© WO 00171693 PCT/GB00/01964
NI -18-
A shuttle retroviral vector is constructed by cloning the bacterial ColE] origin of replication into the multiple cloning site of pLXSN. To create a vector that confers kanamycin resistance in bacteria, a bacterial promoter is inserted upstream of the neomycin s resistance gene by replacing the Sfi I — Rsr II fragment with the Sfi I — Rsr II fragment from pEGFPN1 (Clontech). The resulting vector can replicate in E. coli cells under kanamycin selection. When transduced into mammalian cells expressing the SV40 large-T antigen. it replicates extrachromosomally under neomycin selection. The Mammalian cell - E coli — LTR containing vector is designated pMEL (Figure 4) and has the following features: (1) Kanamycin/Neomycin resistance: allows for selection on kanamycin in £. coli and (G418 in eukaryotic cells. (2) ColE1 Origin of replication: allows for high copy number replication in £. coli (3) SV40 Origin of replication: allows for extrachromosomal replication in eukaryotic cells expressing SV40 large T antigen e.g. COS7 cells (Cepko et al., 1984) pMEL is transformed into Epicurian Coli XL1-Red cells (Stratagene) to introduce random mutations in its sequence. The pool of mutants is extracted using standard large-scale plasmid isolation protocols.
A competition for packaging is set up by co-transfecting 293T cells with equal amounts of the gag-pol expression plasmid, env expression plasmid, Neo-minus pMEL and ten times less of mutagenised pMEL. Vector genomes that are packaged are used to transduce COS cells. They are then isolated from neomycin resistant cells and used to transform XL1-Red cells. The process is repeated to obtain vector genomes with higher packaging efficiencies.
Table 2
Amount of plasmid used for transfection (pg) | Titres (G418 resistant
EE LL LN CH
L
SUBSTITUTE SHEET (RULE 26)
*pLXSN derived vector containing CD8 marker in place of neomycin resistance gene.
Mammalian expression vector similar in size to pLXSCDS.
An initial round of selection with the shuttle vector gave the results shown above in
Table 2.
Thus. competition of pMEL for packaging was successfully set up as observed by the decrease in titres in the presence pLXSCD8. Vector genomes emerging from this selection and competition process are packaged more efficiently. The new high efficiency packaging sites can be engineered into any vector genome of the same viral origin using standard recombinant DNA procedures to produce vector systems generating higher titres.
All publications mentioned in the above specification are herein incorporated by reference. is Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
Adam, M. A. and A. D. Miller (1988). “Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions.” J Virol 62(10): 3802-6.
Allen, P., B. Collins, D. Brown, Z. Hostomsky and L. Gold (1996). “A specific RNA structural motiff mediates high affinity binding by the HIV-1 nucleocapsid protein (NCp7).” Virology 225: 306 - 315.
SUBSTITUTE SHEET (RULE 26)
Beaudry, A. A. and G. F. Joyce (1992). “Directed evolution of an RNA enzyme.” Science 257: 635 - 641.
Berglund. J. A., B. Charpentier and M. Rosbash (1997). “A high affinitv binding site for the HIV-nucleocapsid protein.” Nucleic acids research 25(5): 1042-1049.
Bomnscheuer, U. T., M. M. Enzelberger, J. Altenbuchner and H. H. Mever (1998). “Using
XL1-Red mutator strain to generate esterase variants.” Strategies 11(1): 16 - 17.
Cepko, C.L., B.E. Roberts and R.C. Mulligan. (1984). Cell. 37(3): 1053 -62
Coffin et al “Retroviruses” 1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin,
SM Hughes, HE Varmus pp 758-763.
Joyce, G. F. (1992). “Directed Molecular Evolution.” Scientific American December: 48 - 55. ) Miller, A. D. (1997). Development and applications of retroviral vectors. Retroviruses. J.
M. Coffin, S. H. Hughes and H. E. Varmus, Cold Spring Harbor Press: 437 - 473. ’ 20
Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. C. Griffiths, G. Romano, S. M. Kingsman and A. J. Kingsman (1995). “A transient three-plasmid expression system for the production of high titer retroviral vectors.” Nucleic Acids Res 23(4): 628-33.
Sonstegard, T. S. and P. B. Hackett (1996). “Autogenous regulation of RNA translation and packaging by Rous Sarcoma virus Pr76898.” J. Virol, 70: 6642 - 6652.
Stemmer, W. P. C. (1994). “Rapid evolution of a protein in vitro by DNA shuffling.”
Nature 370: 389 - 391.
Taplitz, R. A. and J. M. Coffin (1997). “Selection of an avian retrovirus mutant with extended receptor usage.” J Virol 71(10): 7814-9.
SUBSTITUTE SHEET (RULE 26)
Claims (21)
1. A method for selecting an improved retroviral genome having an improved packaging efficiency which method comprises: (a) introducing one or more random mutations into a retroviral genome comprising a packaging signal; (b) introducing the mutagenised retroviral genome into a host cell expressing viral polypeptides required for packaging the retroviral genome; (©) determining whether retroviral packaging efficiency in the cell is improved as compared with a retroviral genome comprising a non-mutated packaging signal; (d) selecting a viral genome which has improved packaging efficiency.
2. A method according to claim 1 wherein an additional step (e) of determining the sequence of all or part of the viral genome to identify the sequence of the packaging signal.
3. A method according to claim | or 2 wherein step (a) is carried out in a bacterial strain which introduces random mutations into the retroviral genome.
4. A method according to claim 3 wherein the bacterial strain is a mutagenic strain of Epicurian coli.
3. A method according to any one of the preceding claims wherein the host cell is a mammalian cell.
6. A method according to any one of the preceding claims wherein the host cell comprises at least: (1) a first nucleotide sequence encoding a retroviral gag-pol polypeptide; (il) a second nucleotide sequence encoding a retroviral envelope polypeptide; and (iil) a third nucleotide encoding a retroviral genome comprising a non-mutated packaging signal, wherein the third nucleotide is present as part of a nucleic acid vector which lacks a selectable marker; the mutagenised retroviral genome is present as part of a nucleic acid vector which contains the selectable marker; and the ratio of the vector comprising the SUBSTITUTE SHEET (RULE 26)
Lod, . EA third nucleotide to the vector comprising the mutagenised retroviral genome is greater than 2:1, preferably greater than 5:1.
7. A method according to any one of the preceding claims wherein the packaging efficiency, measured as the proportion of the number of infectious retroviral particles to the total number of retroviral particles produced is greater than 25%.
8. A retroviral genome obtained by the method of any one of the preceding claims.
9. A retroviral genome according to claim 8 having a packaging efficiency, measured as the proportion of the number of infectious retroviral particles to the total number of retroviral particles produced is greater than 25%.
10. A retroviral packaging signal obtainable from a retroviral genome according to claim 8 or 9.
11. A nucleic acid comprising a retroviral packing signal according to claim 10.
12. A retroviral vector comprising a retroviral packing signal according to claim 10.
13. A retroviral vector according to claim 12 for use in producing infectious retroviral particles.
14. A retroviral vector according to claim 12 or 13, which is a lentiviral vector.
15. A producer cell comprising a retroviral genome according to claim 8 or 9. a retroviral packaging signal according to claim 10, or a retroviral vector according to claim 12, 13 or 14.
16. A method for enhancing the efficiency of retroviral packaging which method comprises expressing in a producer cell at least a first nucleotide sequence encoding a retroviral gag-pol polypeptide, a second nucleotide sequence encoding a retroviral envelope polypeptide and a third nucleotide sequence encoding a retroviral genome SUBSTITUTE SHEET (RULE 26)
wherein the ratio of the first nucleotide sequence to the second nucleotide sequence and the ratio of the first nucleotide sequence to the third nucleotide sequence is x:y and x:z. respectively wherein x is less than 1 and y and z are 1.
17. A method according to claim 16 wherein x 1s less than 0.5.
18. A method according to claim 16 or 17 wherein the packaging efficiency, measured as the proportion of the number of infectious retroviral particles to the total number of retroviral particles produced is greater than 25%.
19. A composition comprising infectious retroviral particles produced according to the method of any one of claims 16 to 18.
20. A composition according to claim 19 for use in therapy.
21. A producer cell which expresses at least a first nucleotide sequence encoding a retroviral gag-pol polypeptide, a second nucleotide sequence encoding a retroviral envelope polypeptide and a third nucleotide sequence encoding a retroviral genome wherein the ratio of the first nucleotide sequence to the second nucleotide sequence and the ratio of the first nucleotide sequence to the third nucleotide sequence is x:y and X:z, respectively wherein x is less than 1 and y and z are 1. SUBSTITUTE SHEET (RULE 26)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9911963.8A GB9911963D0 (en) | 1999-05-21 | 1999-05-21 | Method for selecting improved vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200107371B true ZA200107371B (en) | 2002-05-06 |
Family
ID=10853986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200107371A ZA200107371B (en) | 1999-05-21 | 2001-09-06 | Method for selecting improved vectors. |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB9911963D0 (en) |
ZA (1) | ZA200107371B (en) |
-
1999
- 1999-05-21 GB GBGB9911963.8A patent/GB9911963D0/en not_active Ceased
-
2001
- 2001-09-06 ZA ZA200107371A patent/ZA200107371B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB9911963D0 (en) | 1999-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20000049250A (en) | Lentiviral vectors | |
WO2000000600A2 (en) | Lentiviral vectors, comprising modified major donor splice sites and major packaging signals | |
AU719271B2 (en) | Host adaptation of retroviral vectors | |
AU1395400A (en) | Vector | |
CA2237000A1 (en) | Stable packaging cell line producing pseudotyped retroviruses | |
US20050221491A1 (en) | In vivo selection method for determining inhibitory RNA molecules | |
Mautino et al. | Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense | |
US20020119562A1 (en) | Method for selecting improved vectors | |
US7563776B2 (en) | Compositions comprising fusion polypeptides HIV-Nef and NGF, and methods of using the same | |
AU773015B2 (en) | Lentiviral vectors | |
AU2006238617B2 (en) | HIV Vif mutants | |
ZA200107371B (en) | Method for selecting improved vectors. | |
JP2001502884A (en) | Inhibition of HIV-1 replication by antisense RNA expression | |
US20020102537A1 (en) | Retroviral production | |
WO2001004360A9 (en) | Retroviral recombination assays and uses thereof | |
US11965173B2 (en) | Plasmid system | |
US20060067948A1 (en) | Viral vectors | |
EP1183383B1 (en) | Siv-based packaging-deficient vectors | |
WO2011062155A1 (en) | NUCLEIC ACID ENCODING MUTANT Gag PROTEIN | |
Baranick | Characterization and utilization of simple replication-competent retroviral vectors | |
AU2002249393A1 (en) | Viral vectors |